IP Library Granted Patent US 8,586,357
Granted Patent B2
US 8,586,357 · App. 12/093,590 · Granted Nov 19, 2013

Markers of definitive endoderm

Inventors: Kevin Allen D'Amour (San Diego, CA); Alan D Agulnick (San Diego, CA); Emmanuel Edward Baetge (Encinitas, CA)
Assignee: ViaCyte, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,586,357
App. No.
12/093,590
Granted
Nov 19, 2013
Kind
B2
Abstract

Disclosed herein are reagent-cell complexes comprising one or more definitive endoderm cells. Also described herein are compositions for detecting definitive endoderm. Method of enriching, isolating and/or purifying definitive endoderm cells are also disclosed.

Claims (12)

1. An isolated human cell population wherein at least 20% of cells in said cell population form an ex vivo reagent-cell complex comprising:

a human definitive endoderm cell expressing a marker selected from the group consisting of CALCR, CMKOR1, CXCR4, GPR37, NTN4, RTN4RL1, SLC5A9, SLC40A1, and TRPA1, said definitive endoderm cell being a multipotent cell that can differentiate into cells of the gut tube or organs derived therefrom; and

a reagent bound to said marker.

2. The reagent cell complex of claim 1 , wherein said marker comprises a polypeptide selected from the group consisting of CXCR4, GPR37, NTN4, RTN4RL1, SLC40A1, SLC5A9 and TRPA1.

3. The human cell population of claim 1 , wherein at least 40% of said human cells form said ex vivo reagent-cell complex.

4. The human cell population of claim 1 , wherein at least 60% of said human cells form said ex vivo reagent-cell complex.

5. The human cell population of claim 1 , wherein at least 80% of said human cells form said ex vivo reagent-cell complex.

6. An isolated human cell population wherein at least 20% of cells in said cell population form an ex vivo reagent-cell complex comprising:

a human definitive endoderm cell expressing CXCR4, said definitive endoderm cell being a multipotent cell that can differentiate into cells of the gut tube or organs derived therefrom and a reagent bound to CXCR4.

7. The human cell population of claim 6 , wherein at least 40% of said human cells form said ex vivo reagent-cell complex complexes.

8. The human cell population of claim 6 , wherein at least 60% of said human cells form said ex vivo reagent-cell complex.

9. The human cell population of claim 6 , wherein at least 80% of said human cells form said ex vivo reagent-cell complex.

Assignments (3)
MERGER Recorded May 9, 2011
From: CYTHERA, INC.
To: VIACYTE, INC.
Reel/Frame 026256/0613 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2008
From: D'AMOUR, KEVIN ALLEN; AGULNICK, ALAN D.; BAETGE, EMMANUEL EDWARD
To: CYNTHERA, INC.
Reel/Frame 021269/0796 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2008
From: D'AMOUR, KEVIN ALLEN; AGULNICK, ALAN D.; BAETGE, EMMANUEL EDWARD
To: CYTHERA, INC.
Reel/Frame 021269/0801 →
Continuity (6)
Continuation In Part 11021618 · Dec 23, 2004
Provisional Application 60736598 · Nov 14, 2005
Provisional Application 60532004 · Dec 23, 2003
Provisional Application 60586566 · Jul 9, 2004
Provisional Application 60587942 · Jul 14, 2004
Related Publication 20090220959A1 · Sep 3, 2009